Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epiphany Biosciences has initiated a Phase II clinical trial with valomaciclovir for the treatment and management of acute infectious mononucleosis.
Subscribe to our email newsletter
The acute mononucleosis study at the University of Minnesota will mark the first of several planned studies of valomaciclovir against Epstein-Barr virus (EBV) related diseases.
Fred Volinsky, CEO of Epiphany, said: “This initial study in acute mononucleosis will set the stage for broader indications involving EBV as an etiologic agent.”